High-dose therapy with autologous stem cell support in first line treatment of mantle cell lymphoma- 90Y-ibritumomab tiuxetan in combination with BEAM [carmustine, etoposide, cytarabine, melphalan] or BEAC [carmustine, etoposide, cytarabine, cyclophosphamide] to improve outcome for patients not in CR [complete response] after induction treatment.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Melphalan
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 03 May 2012 Actual patient number added 160 according to ClinicalTrials.gov.
- 03 May 2012 Actual patient number added 160 according to ClinicalTrials.gov.
- 03 May 2012 Actual end date (June 2009) added as reported by ClinicalTrials.gov.